Calliditas Therapeutics(CALT) - 2023 Q4 - Earnings Call Transcript

Operator Next page, please. So with regards to Q4, I'd have to start just with some highlights. So obviously the key event for this quarter was on December 20, the FDA granted us full approval of TARPEYO based on the submission of the full Phase 3 data set which we filed in June of 2023. The Phase 3 trial showed a highly statistically significant outcome on the primary endpoint of eGFR with a p value of less than 0.0001. Additional supportive data obviously has been presented on conferences and in other pla ...